News

Aerovate Launches Clinical Trial of AV-101 in PAH

Aerovate Therapeutics is starting a Phase 2b/3 clinical trial that will test AV-101, the company’s experimental inhaled formulation of imatinib, in people with pulmonary arterial hypertension (PAH). “We are excited and humbled to initiate this Phase 2b/Phase 3 trial of AV-101. Starting enrollment represents an important milestone for Aerovate Therapeutics and…

Aerami Therapeutics Goes Public Through SPAC Merger

Aerami Therapeutics, a biopharmaceutical company focused on developing inhaled therapies for severe respiratory diseases — including pulmonary arterial hypertension (PAH) — has entered into a merger agreement with FoxWayne Enterprises Acquisition, a special purpose acquisition company (SPAC). The goal of this merger is to accelerate the development of…

Patterns in HRCT Lung Scans May Predict Survival Rates in IPAH

The presence of specific patterns called centrilobular ground-glass opacifications (cGGOs) in high-resolution computed tomography (HRCT) lung scans is associated with a two-year higher risk of death in people with idiopathic pulmonary arterial hypertension (IPAH), according to a small study in Poland. These findings suggest that chest HRCT data could…

Benefits of PTE Surgery for CTEPH Rapid and Sustained, Study Shows

Pulmonary thromboendarterectomy (PTE) quickly and significantly improved blood flow dynamics and right-sided heart function in people with chronic thromboembolic pulmonary hypertension (CTEPH), with the surgery’s benefits sustained over the long term, a small study shows. Notably, right ventricular (RV) free wall strain, an indirect and non-invasive measure of…

Potential Oral Treatment Reverses Advanced PAH in Rats, Study Shows

An orally available small molecule, BI113823, successfully reversed the progression of severe, advanced pulmonary arterial hypertension (PAH) in a rat model, a study demonstrated. The experimental medicine lowered pulmonary blood pressure, reduced blood vessel thickening, suppressed inflammatory responses, and prevented right heart failure and death. These findings support the…

Respiratory Procedure Eased Breathing in PAH, CTEPH Patients

Adults with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) who have trouble breathing at rest or with light activity may benefit from a procedure called respiratory rate modulation, a pilot, single-center study shows. The three-month procedure also led to lower symptom severity and decreased respiratory…